Cyclacel's seliciclib synergistic with EGFR blocker drugs

20 July 2008

The USA's Cyclacel Pharmaceuticals has reported data from a study showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor inhibitors, including Roche's Tarceva (erlotinib) in models of non-small cell lung cancer, and the HER2-targeting agent Herceptin (trastuzumab) in models of breast cancer.

These preclinical results were published in the July issue of the journal, Clinical Cancer Research. Cyclacel's orally-available cyclin-dependent kinase inhibitor, is currently being tested as a single agent in the Phase IIb APPRAISE trial in patients with non-small cell lung cancer and in a Phase II study in nasopharyngeal cancer.

In the published study, in vitro combination of seliciclib and Herceptin resulted in greater loss of cyclin D1 and increased down-regulation of HER2 than either compound produced independently. Similarly, the combination of seliciclib and EGFR inhibitors resulted in an increased down-regulation of EGFR and greater reduction in cyclin D1 than either compound produced alone. In both studies, the effects on ErbB receptors and cyclin D1 production were expressed as a synergistic inhibition of tumor cell growth, producing significantly greater inhibition than either drug when given alone, the firm noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight